drugset
drugset / Trial / NCT00709540

A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women

NCT00709540 ↗

Phase 1 Completed 40 enrolled Acceleron Pharma, Inc.
RandomizedSingle-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ACE-011 in healthy postmenopausal women.

Timeline

Start
2008-01
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Sotatercept Protein / enzyme biologic — Subcutaneous

Indications

osteoporosis